AR033350A1 - Acidos (aminopropil) metilfosfinicos, su uso para la manufactura de medicamentos, formulacion farmaceutica, e intermediarios - Google Patents

Acidos (aminopropil) metilfosfinicos, su uso para la manufactura de medicamentos, formulacion farmaceutica, e intermediarios

Info

Publication number
AR033350A1
AR033350A1 ARP000106429A ARP000106429A AR033350A1 AR 033350 A1 AR033350 A1 AR 033350A1 AR P000106429 A ARP000106429 A AR P000106429A AR P000106429 A ARP000106429 A AR P000106429A AR 033350 A1 AR033350 A1 AR 033350A1
Authority
AR
Argentina
Prior art keywords
manufacture
pharmaceutical formulation
methylphosphinics
aminopropil
acidos
Prior art date
Application number
ARP000106429A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR033350A1 publication Critical patent/AR033350A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl

Abstract

Acidos (aminopropil) metilfosfínicos, que tienen la siguiente formula 1 donde R1 representa hidrogeno o alquilo inferior, R2 representa un grupo fluor, R3 representa hidrogeno, R4 representa hidrogeno, R5 representa metilo, fluormetilo, difluormetilo, o trifluormetilo; y sus sales, solvatos y enantiomeros farmacéuticamente aceptables, que tiene afinidad con uno o más receptores GABAB, su uso para la manufactura de medicamento, formulacion farmacéutica e intermediarios.
ARP000106429A 1999-12-09 2000-12-05 Acidos (aminopropil) metilfosfinicos, su uso para la manufactura de medicamentos, formulacion farmaceutica, e intermediarios AR033350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904507A SE9904507D0 (sv) 1999-12-09 1999-12-09 New compounds

Publications (1)

Publication Number Publication Date
AR033350A1 true AR033350A1 (es) 2003-12-17

Family

ID=20418062

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106429A AR033350A1 (es) 1999-12-09 2000-12-05 Acidos (aminopropil) metilfosfinicos, su uso para la manufactura de medicamentos, formulacion farmaceutica, e intermediarios

Country Status (27)

Country Link
US (1) US6596711B1 (es)
EP (1) EP1239843A1 (es)
JP (1) JP2003516346A (es)
KR (1) KR100752010B1 (es)
CN (1) CN1200713C (es)
AR (1) AR033350A1 (es)
AU (1) AU780259B2 (es)
BR (1) BR0016291A (es)
CA (1) CA2393510A1 (es)
CO (1) CO5261538A1 (es)
CZ (1) CZ20021984A3 (es)
EE (1) EE200200287A (es)
HK (1) HK1053066A1 (es)
HU (1) HUP0300386A3 (es)
IL (2) IL150090A0 (es)
IS (1) IS6409A (es)
MX (1) MXPA02005537A (es)
NO (1) NO20022729L (es)
NZ (1) NZ519377A (es)
PL (1) PL357115A1 (es)
RU (1) RU2267495C2 (es)
SE (1) SE9904507D0 (es)
SK (1) SK7632002A3 (es)
TW (1) TWI225415B (es)
UA (1) UA73149C2 (es)
WO (1) WO2001041743A1 (es)
ZA (1) ZA200204122B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
TW200407110A (en) 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
DE10305463A1 (de) * 2003-02-04 2004-08-12 Schering Ag Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
SE0402462D0 (sv) * 2004-10-08 2004-10-08 Astrazeneca Ab New process
CA2632021A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
WO2007073298A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
EP2155762B1 (en) 2007-05-04 2011-10-12 AstraZeneca AB Process for the synthesis of alkyl phosphinic acids by initiation of an amine and an amineoxide
US20100317626A1 (en) * 2007-07-25 2010-12-16 Astrazeneca Ab The Use Of (3-Amino-2-Fluoropropyl) Phosphinic Acid For Treatment Of NERD
WO2009082344A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel process for making (2r)-(3-amino-2-fluoropropyl)phosphinic acid form a
WO2009082345A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel crystalline form b of (2r)-(3-amino-2-fluoropropyl)phosphinic acid
JP2011026260A (ja) * 2009-07-28 2011-02-10 Central Glass Co Ltd ３位に脱離基を有する２−フルオロプロピルアミン保護体または該アミンｎ−アルキル保護体
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449046A (de) 1963-07-09 1967-12-31 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
GB8425872D0 (en) 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
WO1987004077A1 (en) 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
GB8820266D0 (en) 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
US5281747A (en) * 1989-05-13 1994-01-25 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
US5567840A (en) * 1989-05-13 1996-10-22 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
GB8911017D0 (en) * 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
FR2663934B1 (fr) 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
FR2722192A1 (fr) 1994-07-06 1996-01-12 Adir Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9420784D0 (en) 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
SE9603408D0 (sv) 1996-09-18 1996-09-18 Astra Ab Medical use

Also Published As

Publication number Publication date
RU2002113916A (ru) 2004-01-10
AU2241201A (en) 2001-06-18
KR100752010B1 (ko) 2007-08-28
SE9904507D0 (sv) 1999-12-09
EE200200287A (et) 2003-08-15
BR0016291A (pt) 2002-08-13
NO20022729D0 (no) 2002-06-07
IS6409A (is) 2002-06-06
MXPA02005537A (es) 2004-09-10
EP1239843A1 (en) 2002-09-18
AU780259B2 (en) 2005-03-10
CZ20021984A3 (cs) 2002-11-13
US6596711B1 (en) 2003-07-22
KR20020060993A (ko) 2002-07-19
UA73149C2 (en) 2005-06-15
TWI225415B (en) 2004-12-21
PL357115A1 (en) 2004-07-12
SK7632002A3 (en) 2003-03-04
RU2267495C2 (ru) 2006-01-10
NZ519377A (en) 2003-11-28
HUP0300386A3 (en) 2005-08-29
WO2001041743A1 (en) 2001-06-14
CN1200713C (zh) 2005-05-11
JP2003516346A (ja) 2003-05-13
IL150090A (en) 2006-08-01
CO5261538A1 (es) 2003-03-31
IL150090A0 (en) 2002-12-01
HUP0300386A2 (hu) 2003-07-28
HK1053066A1 (en) 2003-10-10
ZA200204122B (en) 2003-10-29
NO20022729L (no) 2002-07-09
CN1413104A (zh) 2003-04-23
CA2393510A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
AR033350A1 (es) Acidos (aminopropil) metilfosfinicos, su uso para la manufactura de medicamentos, formulacion farmaceutica, e intermediarios
AR030541A1 (es) Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica
UY27740A1 (es) Nuevos compuestos
AR015157A1 (es) DERIVADOS DEL ÁCIDO 5-ALQUIL-2-ARILAMINOFENILÁCETICO, COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE, SU USO EN LA MANUFACTURA DE UN MEDICAMENTO Y MÉTODO DE PREPARACIoN DEL MISMO
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
AR077416A2 (es) Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos
ATE297910T1 (de) Retinoid x rezeptormodulatoren
EA200300999A1 (ru) Хронотерапевтические дозированные формы
DK0797439T3 (da) Anvendelse af pramipexol som et neurobeskyttende middel
ES2130686T3 (es) Procedimiento para la preparacion de metalocenil-fosfinas opticamente activas.
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
CU23288B7 (es) DERIVADOS DE TROPANO ÃsTILES EN TERAPIA
AR021355A1 (es) Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
DK0675717T3 (da) Anvendelse af 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol (pramipexol) som lægemiddel med antidepressiv virknin
ES2187261B2 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
FI945581A0 (fi) Substituoidut (aryylialkoksibentsyyli) aminopropaaniamidijohdannaiset, niiden valmistus ja käyttö antiepileptisinä, neuroprotektiivisina ja antidepressiivisinä aineina
AR007088A1 (es) 2,4-diaminopirimidinas sustituidas, compuestos intermedios utilizados en su preparacion, procedimiento para la preparacion de dichas 2,4-diaminopirimidinas sustituidas, medicamentos que las contienen y empleos de dichas pirimidinas
AR035110A1 (es) Compuesto derivado de piperazina, uso del mismo para la preparacion de una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
BR9812085A (pt) "método para a sìntese de derivados de quinolina"
ES2189072T3 (es) Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR042404A2 (es) Compuestos derivados de anilina
SV1999000075A (es) Derivados de 3-(2-oxo-[1,3']bipirrolidinil-3-ilidenemetil)-cefemos

Legal Events

Date Code Title Description
FB Suspension of granting procedure